Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065806 | 0.75 | POLB (0.50) | DRD2HTR2ADRD3 | |
| SCHEMBL15402450 | 0.75 | CHRNB2 (0.43) | DRD2DRD3 | |
| SCHEMBL2210707 | 0.75 | NPC1 (0.63) | NPC1RAB9ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL917757 | 0.74 | POLB (0.49) | DRD2HTR2ADRD3 | |
| SCHEMBL27607725 | 0.74 | KCNH2 (0.47) | NPC1RAB9ADRD2HTR2A | |
| SCHEMBL1626963 | 0.73 | DRD2 (0.65) | DRD2HTR2ADRD3 | |
| SCHEMBL4536932 | 0.73 | DRD2 (0.65) | DRD2HTR2ADRD3 | |
| SCHEMBL357358 | 0.73 | DRD2 (0.65) | DRD2HTR2ADRD3 | |
| SCHEMBL8538844 | 0.73 | DRD2 (0.65) | DRD2HTR2ADRD3 | |
| SCHEMBL27166460 | 0.72 | DRD2 (0.39) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | NPC1 468/4885RAB9A 3174/4885DRD2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.